



J&JPRD Media Contact:

Ernie Knewitz, Media

908-927-2953

**Results From Two Phase III Studies of Rivaroxaban Published in
*The New England Journal of Medicine***

Raritan, NJ (June 25, 2008) -- Data from two previously reported Phase III clinical trials demonstrating that the oral, once-daily, investigational anticoagulant rivaroxaban is significantly more effective than enoxaparin, the current standard of care, in preventing venous blood clots in total hip or knee replacement surgery patients were published today in *The New England Journal of Medicine*. The full article can be accessed through the following link www.nejm.org.

Results from these head-to-head trials, known as RECORD1 and RECORD3, were previously presented at the annual meeting of the American Society of Hematology in December 2007.

Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare AG.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is a wholly-owned subsidiary of Johnson & Johnson, the world's most broadly based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. More information can be found at <http://www.jnjpharmarnd.com>.

###